Accretion Pharmaceuticals Ltd Financials
Company Logo

Accretion Pharmaceuticals Ltd Financial Statement

Accretion Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Accretion Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual57.38
Operating Expenses Annual45.50
Operating Profit Annual11.98
Interest Annual1.44
Depreciation0.77
Net Profit Annual6.79
Tax Annual2.97

Accretion Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.09
Cash Flow from Operations5.75
Cash Flow from Investing-1.61
Cash Flow from Financing-4.18
Cash Flow at the End0.05

Accretion Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)20.88
PBIT Margin (%)19.54
PBT Margin (%)5.98
Net PROFIT Margin (%)11.83
Return On Networth / Equity (%)65.35
Return On Networth /Employed (%)46.32
Return On Assets (%)28.05
Total Debt / Equity (X)1.33
Asset Turnover Ratio (%)2.37

Accretion Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual6.09
Total Current Assets Annual33.55
Non Current Assets Annual6.33
Total Shareholders Funds Annual15.29
Total Assets Annual39.87

Accretion Pharmaceuticals Ltd Earning Calls

No Data Availabe

FAQS on Accretion Pharmaceuticals Ltd Financials

As of Sep 24, 2025, Accretion Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Accretion Pharmaceuticals Ltd is not with a debt-to-equity ratio of 0.92.

In FY 2024 , Accretion Pharmaceuticals Ltd recorded a total revenue of approximately 57.38 Cr marking a significant milestone in the company's financial performance.

Accretion Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.3% annually, respectively..

Accretion Pharmaceuticals Ltd's current PE ratio is .

Accretion Pharmaceuticals Ltd's ROCE averaged 20.2% from the FY ending March 2023 to 2025, with a median of 12.6%. It peaked at 38.1% in March 2025, reflecting strong capital efficiency over the period..

Accretion Pharmaceuticals Ltd's latest EBIT is Rs. 11.20 Cr, surpassing the average EBIT of Rs. 4.94 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions